Camellia (300723.SZ): Subsidiary's innovative drug APH03867 tablets receive clinical trial registration application acceptance.

According to the Zhitong Finance APP, Yipin Red (300723.SZ) announced that recently, the company's wholly-owned subsidiary, Guangzhou Yipin Red Pharmaceutical Co., Ltd., obtained the acceptance of the application for clinical trials of the innovative drug APH03867 tablets independently developed by the company, from the National Medical Products Administration, and received the "Acceptance Notification Letter".